Objective: Cytopathologic interpretation in Graves disease (GD) is considered challenging due to significant cellular atypia. Study Design: We retrospectively identified 55 fine needle aspirations (FNAs) from 43 patients with GD that subsequently underwent thyroidectomy from 1995 to 2016. Results: There were 5 patients with papillary thyroid carcinoma (PTC) and 4 with follicular adenoma (FA). Of the 5 patients with PTC, FNA was interpreted as PTC in 3, atypia of undetermined significance (AUS) in 1, and adenomatoid nodule (AN) in 1 (with a 0.5-cm incidental microcarcinoma). Of the 4 patients with FA, FNA was interpreted as follicular neoplasm (FN) in 2, AUS in 1, and AN in 1. Of the 46 nonneoplastic nodules, FNA was interpreted as nondiagnostic in 2, benign in 26, AUS in 15, FN in 1, and suspicious for PTC in 2. None was diagnosed as malignant. The sensitivity, specificity, positive predictive value, and negative predictive value of PTC diagnosis in FNA were 60, 100, 100, and 96.2%, respectively. Conclusion: FNA is a useful tool for identifying neoplastic nodules arising in GD. However, cytologic atypia often leads to indeterminate diagnoses (18/46, 39.1%). Awareness of clinical information regarding prior treatment for GD may be helpful to avoid overinterpretation.

1.
Brent GA: Clinical practice. Graves' disease. N Engl J Med 2008;358:2594-2605.
2.
Burch HB, Cooper DS: Management of Graves disease: a review. JAMA 2015;314:2544-2554.
3.
Belfiore A, Russo D, Vigneri R, Filetti S: Graves' disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) 2001;55:711-718.
4.
Kraimps JL, Bouin-Pineau MH, Mathonnet M, De Calan L, Ronceray J, Visset J, Marechaud R, Barbier J: Multicentre study of thyroid nodules in patients with Graves' disease. Br J Surg 2000;87:1111-1113.
5.
Gerenova J, Buysschaert M, de Burbure CY, Daumerie C: Prevalence of thyroid cancer in Graves' disease: a retrospective study of a cohort of 103 patients treated surgically. Eur J Intern Med 2003;14:321-325.
6.
Pellegriti G, Mannarino C, Russo M, Terranova R, Marturano I, Vigneri R, Belfiore A: Increased mortality in patients with differentiated thyroid cancer associated with Graves' disease. J Clin Endocrinol Metab 2013;98:1014-1021.
7.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
8.
Centeno BA, Szyfelbein WM, Daniels GH, Vickery AL Jr: Fine needle aspiration biopsy of the thyroid gland in patients with prior Graves' disease treated with radioactive iodine. Morphologic findings and potential pitfalls. Acta Cytol 1996;40:1189-1197.
9.
Granter SR, Cibas ES: Cytologic findings in thyroid nodules after 131I treatment of hyperthyroidism. Am J Clin Pathol 1997;107:20-25.
10.
Sturgis CD: Radioactive iodine-associated cytomorphologic alterations in thyroid follicular epithelium: is recognition possible in fine-needle aspiration specimens? Diagn Cytopathol 1999;21:207-210.
11.
Anderson SR, Mandel S, LiVolsi VA, Gupta PK, Baloch ZW: Can cytomorphology differentiate between benign nodules and tumors arising in Graves' disease? Diagn Cytopathol 2004;31:64-67.
12.
Ali SZ, Cibas ES: The Bethesda System for Reporting Thyroid Cytopathology. Definitions, Criteria and Explanatory Notes. New York, Springer, 2010.
13.
Carnell NE, Valente WA: Thyroid nodules in Graves' disease: classification, characterization, and response to treatment. Thyroid 1998;8:571-576.
14.
Cantalamessa L, Baldini M, Orsatti A, Meroni L, Amodei V, Castagnone D: Thyroid nodules in Graves disease and the risk of thyroid carcinoma. Arch Intern Med 1999;159:1705-1708.
15.
Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee HK, Hong SJ, Shong YK: Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) 2004;60:719-725.
16.
Jayaram G, Singh B, Marwaha RK: Grave's disease. Appearance in cytologic smears from fine needle aspirates of the thyroid gland. Acta Cytol 1989;33:36-40.
17.
Smejkal V, Smejkalova E, Rosa M, Zeman V, Smetana K: Cytologic changes simulating malignancy in thyrotoxic goiters treated with carbimazole. Acta Cytol 1985;29:173-178.
18.
Zhang M, Lin O: Molecular testing of thyroid nodules: a review of current available tests for fine-needle aspiration specimens. Arch Pathol Lab Med 2016;140:1338-1344.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.